Annexon, Inc. (ANNX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$4.37-6.42%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Annexon aims to fund operations into the second half of 2027. It has advanced pipeline catalysts supporting late-stage program milestones. Analysts have revised EPS estimates up recently from -1.16 to -0.98 for 2026. The company reported multiple earnings beats in 2026.
Annexon remains loss-making with negative EPS around -0.98 in 2026. It has no current revenue and depends on successful late-stage trials. Failure to achieve milestones or raise capital beyond 2027 would hurt the stock.
The market currently prices in continued losses with EPS near -0.98 in 2026 and no revenue. Our view differs by focusing on the risk of milestone failures and funding beyond 2027, which are not fully reflected in the price.
Breaks if: Misses or delays key late-stage program milestones in 2026
Breaks if: Fails to secure funding to operate beyond mid-2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as ANNX is focused on advancing late-stage clinical programs. The current thesis state is cautious, reflecting recent earnings misses and a need for strong execution in upcoming milestones.
The market appears to be pricing in a low confidence level, given the company's loss-making status and recent financial performance that lags behind peers. Elevated risk factors are also likely influencing investor sentiment.
Management is actively investing in clinical trials, which may support future growth, but the company remains loss-making. The recent financial performance has been neutral, and while there is a low probability of missing estimates, the overall industry has seen higher miss rates lately.
Key forward scenarios include the potential for unfavorable guidance cuts or economic downturns affecting the healthcare sector. Conversely, positive momentum from sector leaders could provide a beneficial lift to ANNX.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report missed expectations. This miss raises concerns about the company's financial performance. There are no new supportive factors to offset this weakness.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -1.16 in FY26 or fails to improve in FY27
Over the next 1 to 3 years, ANNX's success will depend on its ability to execute on clinical milestones and navigate market challenges. Not investment advice.